Molecular phenotypes of breast cancer and their clinical application

Chinese Journal of Pathology

Volumn 38, Issue 1, 2009, Pages 13-17

  Tang, Ping ^a   Wei, Bing ^a   Hicks, David G ^a   Skinner, Kristin ^a   Bu, Hong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; UVOMORULIN;

BREAST CANCER; CLINICAL ASSESSMENT; MOLECULAR BIOLOGY; NOTE; PHENOTYPE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTOKINES; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 59049093151     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2009.01.005     Document Type: Note

References (35)

1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med, 2004, 351(27) : 2817-2826.
2. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415(6871) : 530-536.
3. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol, 2006,24(11) : 1665-1671.
4. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA, 2005, 102(10) : 3738-3743.
5. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 2004, 5(6) : 607-616.
6. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med, 2006, 355(6) : 560-569.
7. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797) : 747-752.
8. Sørlie T, Perou CM, Tibshirani R,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 2001, 98(19) : 10869-10874.
9. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 2003,100(14) : 8418-8423.
10. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol, 2002, 198(4) : 458-467.
11. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest, 2002, 82 (11) : 1525-1533.
12. Tang P, Wang X, Schiffhauer L, et al. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci, 2006, 36(1) : 16-22.
13. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol, 2005, 18(10) : 1321-1328.
14. Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol, 2005,207(3) : 260-268.
15. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast : patterns of metastasis and long-term survival. Breast Cancer Res, 2007, 9 ( 1) : R4.
16. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 2006, 59(7) :729-735.
17. Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal carcinomas with different clinical outcomes. Clin Can Res, 2004, 10 (18 part 1) :5988-5997.
18. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer. Cancer, 2007, 109(1) : 25-32.
19. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. A population-based study from the California Cancer Registry. Cancer, 2007, 109(9) :1721-1728.
20. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer : molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 2008, 111(1) :2744.
21. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10(16) : 5367-5374.
22. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 2006, 19(2) : 264-271.
23. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer, 2005, 116(3) : 340-350.
24. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295(21) :2492-2502.
25. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions, are they the same? Hum Pathol, 2008, 39(4) : 506-513.
26. Early Breast Cancer Trialist' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 2005, 365(9472) : 1687-1717.
27. Rourier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 2005, 11(16) : 5678-5685.
28. Goldstein S, Decker D, Severson D, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 2007, 110(8) :1687-1696.
29. Troester MA, Hoadley KA, Sorlie T, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res, 2004, 64(12) ; 4218-4226.
30. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol, 2007, 60(9) : 1006-1012.
31. Colditz GA, Rosner BA, Chen WY, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Nalt Cancer Inst, 2004, 96(3) : 218-228.
32. Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res, 2006, 12 (14 part 1) :41854191.
33. Sidoni A, Cartaginese F, Colozza M, et al. ERCC1 expression in triple negative breast carcinoma: the paradox revisited. Breast Cancer Res Treat, 2008, 111(3) : 569-670.
34. Kreike B, van Kouwenhove M, Horlings B, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res, 2007, 9 (5) : R65.
35. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypical analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol, 2006, 208(4) : 495-506.